US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

SPYRE THERAPEUTICS INC

89.33

-1.0300-1.14%

Post-market: 89.15-0.1800-0.20%17:32 EDT

Volume:1.91M

Turnover:169.53M

Market Cap:7.88B

PE:-44.44

High:90.97

Open:89.15

Low:86.40

Close:90.36

52wk High:110.18

52wk Low:14.51

Shares:88.17M

Float Shares:80.98M

Volume Ratio:1.35

T/O Rate:2.36%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.0100

EPS(LYR):-1.9755

ROE:-22.98%

ROA:-19.81%

PB:8.25

PE(LYR):-45.22

Loading ...

Overview Company News Filings

Spyre Therapeutics announces SKYLINE trial achieves primary endpoint

Spyre says SPY002 hits primary endpoint in Phase 2 SKYLINE ulcerative colitis trial Part A induction data

Spyre Therapeutics - Spy002 Meets Primary Endpoint With 10.7-Point Rhi Reduction at Week 12

THOMSON REUTERS

Spyre Announces Potential Best-in-Class Spy002 (Anti-Tl1a) Part a Induction Results From Skyline Trial in Moderate-to-Severe Ulcerative Colitis Patients

THOMSON REUTERS

Spyre Therapeutics - Spy002 Well Tolerated With Safety Profile Consistent With Tl1a Class

THOMSON REUTERS

Spyre Therapeutics - Spy002 Achieves 33% Clinical Remission and 42% Endoscopic Improvement at Week 12

THOMSON REUTERS

Spyre Therapeutics - Twenty Subjects Had Treatment-Emergent Adverse Events; Two Serious, None Drug-Related

THOMSON REUTERS

Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Cogstate Ltd (COGZF)

S&P 500 Futures Climb In Premarket Trading; Navan, AXT Lead

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics : Deutsche Bank Raises Target Price to $115 From $102

THOMSON REUTERS

Spyre Therapeutics CMO Sheldon Sloan disposes of USD 624,975 in common shares

Spyre Therapeutics CEO Cameron Turtle disposes of USD 1.04 million in common shares

Spyre Therapeutics CFO Scott L Burrows disposes of common shares worth $534,123.87

Assessing Spyre Therapeutics (SYRE) Valuation After Expanded SPY003 License With Paragon

Simply Wall St.

Spyre Therapeutics Completes Enrollment in Phase 2 SKYWAY Trial of SPY072 in Rheumatic Diseases

MT Newswires Live

Spyre Therapeutics - Across Skyway and Skyline Trials, Planned ‘6 in ’26’ Phase 2 Readouts Enabled and on Track

THOMSON REUTERS

Spyre Therapeutics - Reiterates Expected Q3 2026 Readout for Rheumatoid Arthritis (Ra) and Q4 2026 Readouts for Psa and Axspa

THOMSON REUTERS

Spyre Therapeutics Announces Completion of Enrollment in Skyway Basket Trial Evaluating Spy072 (Anti-Tl1a) in Ra, Psa, and Axspa

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/SYRE/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SYRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","market":"US","secType":"STK","nameCN":"SPYRE THERAPEUTICS INC","latestPrice":89.33,"timestamp":1788206400000,"preClose":90.36,"halted":0,"volume":1913157,"hourTrading":{"tag":"盘后","latestPrice":89.15,"preClose":89.33,"latestTime":"17:32 EDT","volume":254835,"amount":22764402.90495,"timestamp":1788211933174,"change":-0.18,"changeRate":-0.002015,"amplitude":0.005217},"delay":0,"changeRate":-0.01139884904825145,"floatShares":80977000,"shares":88173800,"eps":-2.009956,"marketStatus":"Post-Mkt","change":-1.03,"latestTime":"08-31 18:46:24 EDT","open":89.15,"high":90.965,"low":86.4,"amount":169534790.1864,"amplitude":0.05052,"askPrice":89.32,"askSize":3,"bidPrice":87.59,"bidSize":22,"shortable":3,"etf":0,"ttmEps":-2.009956,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":4,"adr":0,"listingDate":1460001600000,"exchange":"NASDAQ","adjPreClose":90.36,"preHourTrading":{"tag":"盘前","latestPrice":88.13,"preClose":90.36,"latestTime":"09:29 EDT","volume":763,"amount":68221.45519000001,"timestamp":1788182999999,"change":-2.23,"changeRate":-0.024679,"amplitude":0.02479},"postHourTrading":{"tag":"盘后","latestPrice":89.15,"preClose":89.33,"latestTime":"17:32 EDT","volume":254835,"amount":22764402.90495,"timestamp":1788211933174,"change":-0.18,"changeRate":-0.002015,"amplitude":0.005217},"volumeRatio":1.345119,"impliedVol":0.8996,"impliedVolPercentile":0.7729},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","floatShares":80977000,"roa":"-19.81%","roe":"-22.98%","lyrEps":-1.975476,"volumeRatio":1.345119,"shares":88173800,"dividePrice":0,"high":90.965,"amplitude":0.05052,"preClose":90.36,"low":86.4,"week52Low":14.505,"pbRate":"8.25","week52High":110.175,"institutionHeld":0,"latestPrice":89.33,"committee":0.76,"eps":-2.009956,"divideRate":0,"volume":1913157,"delay":0,"ttmEps":-2.009956,"open":89.15,"prevYearClose":32.76,"prevWeekClose":90.36,"prevMonthClose":98.33,"prevQuarterClose":88.78,"fiveDayClose":106.65,"twentyDayClose":94.93,"sixtyDayClose":78.48},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SYRE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-04","symbol":"SYRE","fiscalQuarterEnding":"2026/06","expectedEps":-0.71,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785816000000,"reportTimeType":"post","actualEps":-0.36},{"market":"US","date":"2026-05-05","symbol":"SYRE","fiscalQuarterEnding":"2026/03","expectedEps":-0.66,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1777953600000,"reportTimeType":"pre","actualEps":-0.74},{"market":"US","date":"2026-02-19","symbol":"SYRE","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1771477200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-04","symbol":"SYRE","fiscalQuarterEnding":"2025/09","expectedEps":-0.68,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762232400000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2025-08-05","symbol":"SYRE","fiscalQuarterEnding":"2025/06","expectedEps":-0.73,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"post","actualEps":-0.49}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SYRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SYRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5294,"buy":0.4118,"hold":0.0588,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4118,"analysts":17,"updateTime":1785470400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SYRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SYRE","date":"2026-08-28","current":-44.443759,"percent":0.049635,"low":-53.677585,"twenty":-18.037414,"median":-6.00579,"eighty":-4.082736,"high":-0.199399,"avg":-12.382014,"sd":13.405227,"marketCap":8254386729},"quantilePoints":[{"date":"2023-12-01","current":-1.902619,"twenty":-1.228042,"median":-0.216176,"eighty":-0.20611,"marketCap":560191990},{"date":"2023-12-08","current":-2.024974,"twenty":-2.048834,"median":-1.98164,"eighty":-0.890753,"marketCap":596217199},{"date":"2023-12-15","current":-1.815535,"twenty":-2.023412,"median":-1.966856,"eighty":-1.735642,"marketCap":534551743},{"date":"2023-12-22","current":-2.106706,"twenty":-2.023412,"median":-1.950531,"eighty":-1.82549,"marketCap":620281740},{"date":"2023-12-29","current":-2.507984,"twenty":-2.09023,"median":-1.996425,"eighty":-1.840422,"marketCap":738430643},{"date":"2024-01-05","current":-2.757559,"twenty":-2.278228,"median":-2.002935,"eighty":-1.873937,"marketCap":811913497},{"date":"2024-01-12","current":-2.567931,"twenty":-2.588728,"median":-2.024974,"eighty":-1.89995,"marketCap":756080936},{"date":"2024-01-19","current":-2.66458,"twenty":-2.653814,"median":-2.09023,"eighty":-1.902486,"marketCap":784537532},{"date":"2024-01-26","current":-3.303198,"twenty":-2.742878,"median":-2.292052,"eighty":-1.915254,"marketCap":972567189},{"date":"2024-02-02","current":-3.16373,"twenty":-3.116751,"median":-2.567931,"eighty":-1.947266,"marketCap":931503241},{"date":"2024-02-09","current":-2.89825,"twenty":-3.138772,"median":-2.61809,"eighty":-1.978684,"marketCap":853337655},{"date":"2024-02-16","current":-2.760005,"twenty":-3.112591,"median":-2.66458,"eighty":-1.997649,"marketCap":812633917},{"date":"2024-02-23","current":-2.496973,"twenty":-3.08641,"median":-2.66458,"eighty":-2.000865,"marketCap":735188752},{"date":"2024-03-01","current":-3.357028,"twenty":-3.117974,"median":-2.696389,"eighty":-2.009323,"marketCap":988416432},{"date":"2024-03-08","current":-4.14553,"twenty":-3.186241,"median":-2.748383,"eighty":-2.021849,"marketCap":1404464057},{"date":"2024-03-15","current":-4.473117,"twenty":-3.315921,"median":-2.757559,"eighty":-2.032927,"marketCap":1515447446},{"date":"2024-03-22","current":-4.253303,"twenty":-3.374155,"median":-2.84075,"eighty":-2.069838,"marketCap":1440976508},{"date":"2024-03-28","current":-3.948124,"twenty":-3.948124,"median":-2.884793,"eighty":-2.09023,"marketCap":1337584817},{"date":"2024-04-05","current":-3.822655,"twenty":-3.997689,"median":-2.933117,"eighty":-2.106706,"marketCap":1295077328},{"date":"2024-04-12","current":-4.169482,"twenty":-4.017483,"median":-2.950857,"eighty":-2.22293,"marketCap":1412578691},{"date":"2024-04-19","current":-3.844264,"twenty":-4.019298,"median":-3.071974,"eighty":-2.361175,"marketCap":1302398285},{"date":"2024-04-26","current":-3.508242,"twenty":-4.017483,"median":-3.149049,"eighty":-2.496973,"marketCap":1188557401},{"date":"2024-05-03","current":-4.312212,"twenty":-4.026871,"median":-3.180093,"eighty":-2.505537,"marketCap":1460934345},{"date":"2024-05-10","current":-4.183809,"twenty":-4.050631,"median":-3.290964,"eighty":-2.507984,"marketCap":1417432578},{"date":"2024-05-17","current":-4.180278,"twenty":-4.096445,"median":-3.334395,"eighty":-2.567931,"marketCap":1522561849},{"date":"2024-05-24","current":-3.614061,"twenty":-4.096445,"median":-3.364368,"eighty":-2.569154,"marketCap":1316331249},{"date":"2024-05-31","current":-4.872934,"twenty":-4.111605,"median":-3.38639,"eighty":-2.608303,"marketCap":1774844320},{"date":"2024-06-07","current":-4.694469,"twenty":-4.171641,"median":-3.527045,"eighty":-2.61809,"marketCap":1709842869},{"date":"2024-06-14","current":-4.393309,"twenty":-4.193693,"median":-3.59738,"eighty":-2.63375,"marketCap":1600152919},{"date":"2024-06-21","current":-3.360163,"twenty":-4.181695,"median":-3.573485,"eighty":-2.653814,"marketCap":1223855454},{"date":"2024-06-28","current":-3.277902,"twenty":-4.180281,"median":-3.545724,"eighty":-2.666048,"marketCap":1193893847},{"date":"2024-07-05","current":-3.553965,"twenty":-4.180278,"median":-3.545724,"eighty":-2.674367,"marketCap":1294442968},{"date":"2024-07-12","current":-4.13816,"twenty":-4.17596,"median":-3.564426,"eighty":-2.694186,"marketCap":1507221157},{"date":"2024-07-19","current":-4.113063,"twenty":-4.180278,"median":-3.593701,"eighty":-2.712782,"marketCap":1498080328},{"date":"2024-07-26","current":-4.387732,"twenty":-4.219183,"median":-3.614061,"eighty":-2.731867,"marketCap":1598121624},{"date":"2024-08-02","current":-3.651563,"twenty":-4.192391,"median":-3.674487,"eighty":-2.752053,"marketCap":1329990636},{"date":"2024-08-09","current":-6.773008,"twenty":-4.238871,"median":-3.689208,"eighty":-2.757559,"marketCap":1259650875},{"date":"2024-08-16","current":-7.111659,"twenty":-4.267009,"median":-3.707046,"eighty":-2.757559,"marketCap":1322633418},{"date":"2024-08-23","current":-6.972375,"twenty":-4.305721,"median":-3.744862,"eighty":-2.758537,"marketCap":1296729308},{"date":"2024-08-30","current":-7.851774,"twenty":-4.372067,"median":-3.796365,"eighty":-2.792303,"marketCap":1460280752},{"date":"2024-09-06","current":-7.655166,"twenty":-4.395693,"median":-3.839237,"eighty":-2.844176,"marketCap":1423715511},{"date":"2024-09-13","current":-8.038472,"twenty":-4.515004,"median":-3.909092,"eighty":-2.863261,"marketCap":1495003126},{"date":"2024-09-20","current":-8.260242,"twenty":-4.753435,"median":-3.923931,"eighty":-2.887484,"marketCap":1536248103},{"date":"2024-09-27","current":-7.800275,"twenty":-4.893011,"median":-3.931452,"eighty":-2.904612,"marketCap":1450702965},{"date":"2024-10-04","current":-7.980976,"twenty":-5.268067,"median":-3.990592,"eighty":-2.931282,"marketCap":1484309983},{"date":"2024-10-11","current":-7.857771,"twenty":-6.760445,"median":-4.004311,"eighty":-2.936176,"marketCap":1461396107},{"date":"2024-10-18","current":-8.969358,"twenty":-6.959266,"median":-4.01434,"eighty":-2.939112,"marketCap":1668130191},{"date":"2024-10-25","current":-9.530627,"twenty":-7.262959,"median":-4.019298,"eighty":-2.969942,"marketCap":1772515627},{"date":"2024-11-01","current":-9.303382,"twenty":-7.505129,"median":-4.04736,"eighty":-3.046528,"marketCap":1730252255},{"date":"2024-11-08","current":-9.47125,"twenty":-7.585076,"median":-4.070861,"eighty":-3.057293,"marketCap":2035390531},{"date":"2024-11-15","current":-6.988263,"twenty":-7.603794,"median":-4.087936,"eighty":-3.101825,"marketCap":1501791624},{"date":"2024-11-22","current":-7.566995,"twenty":-7.593388,"median":-4.106049,"eighty":-3.128495,"marketCap":1626162294},{"date":"2024-11-29","current":-7.766414,"twenty":-7.602508,"median":-4.133831,"eighty":-3.149049,"marketCap":1669017834},{"date":"2024-12-06","current":-7.397625,"twenty":-7.602508,"median":-4.146835,"eighty":-3.16373,"marketCap":1589764437},{"date":"2024-12-13","current":-6.589022,"twenty":-7.597044,"median":-4.169482,"eighty":-3.166361,"marketCap":1415994026},{"date":"2024-12-20","current":-6.517996,"twenty":-7.595055,"median":-4.180278,"eighty":-3.169847,"marketCap":1400730409},{"date":"2024-12-27","current":-6.466093,"twenty":-7.588386,"median":-4.182047,"eighty":-3.186241,"marketCap":1389576227},{"date":"2025-01-03","current":-6.651853,"twenty":-7.58308,"median":-4.215671,"eighty":-3.191991,"marketCap":1429496457},{"date":"2025-01-10","current":-6.135549,"twenty":-7.579794,"median":-4.247699,"eighty":-3.203592,"marketCap":1318541701},{"date":"2025-01-17","current":-5.632904,"twenty":-7.573901,"median":-4.253955,"eighty":-3.236074,"marketCap":1210522256},{"date":"2025-01-24","current":-5.900617,"twenty":-7.564263,"median":-4.27898,"eighty":-3.264517,"marketCap":1268054352},{"date":"2025-01-31","current":-6.280332,"twenty":-7.548513,"median":-4.304099,"eighty":-3.280514,"marketCap":1349655997},{"date":"2025-02-07","current":-6.187452,"twenty":-7.528128,"median":-4.345056,"eighty":-3.293411,"marketCap":1329695883},{"date":"2025-02-14","current":-6.26121,"twenty":-7.522652,"median":-4.382852,"eighty":-3.305947,"marketCap":1345546562},{"date":"2025-02-21","current":-5.815932,"twenty":-7.518271,"median":-4.394799,"eighty":-3.316941,"marketCap":1249855423},{"date":"2025-02-28","current":-5.708297,"twenty":-7.512359,"median":-4.473117,"eighty":-3.319102,"marketCap":1187428551},{"date":"2025-03-07","current":-5.647447,"twenty":-7.483663,"median":-4.605135,"eighty":-3.349687,"marketCap":1174770683},{"date":"2025-03-14","current":-5.227293,"twenty":-7.452562,"median":-4.749486,"eighty":-3.357028,"marketCap":1087371120},{"date":"2025-03-21","current":-5.264962,"twenty":-7.449529,"median":-4.833391,"eighty":-3.360163,"marketCap":1095206943},{"date":"2025-03-28","current":-5.198317,"twenty":-7.397625,"median":-4.89803,"eighty":-3.364368,"marketCap":1081343564},{"date":"2025-04-04","current":-3.706047,"twenty":-7.375771,"median":-4.833391,"eighty":-3.376602,"marketCap":770924425},{"date":"2025-04-11","current":-3.540883,"twenty":-7.371109,"median":-4.749486,"eighty":-3.378289,"marketCap":736567355},{"date":"2025-04-17","current":-3.671275,"twenty":-7.352984,"median":-4.694469,"eighty":-3.38477,"marketCap":763691357},{"date":"2025-04-25","current":-4.094327,"twenty":-7.328784,"median":-4.51381,"eighty":-3.412624,"marketCap":851693676},{"date":"2025-05-02","current":-4.378293,"twenty":-7.296115,"median":-4.473117,"eighty":-3.422161,"marketCap":910763726},{"date":"2025-05-09","current":-4.072986,"twenty":-7.269514,"median":-4.422481,"eighty":-3.450063,"marketCap":850985210},{"date":"2025-05-16","current":-4.384959,"twenty":-7.258044,"median":-4.393309,"eighty":-3.492778,"marketCap":916167055},{"date":"2025-05-23","current":-4.353184,"twenty":-7.252035,"median":-4.386346,"eighty":-3.506946,"marketCap":909528164},{"date":"2025-05-30","current":-4.491839,"twenty":-7.242247,"median":-4.381626,"eighty":-3.527827,"marketCap":938497873},{"date":"2025-06-06","current":-4.800924,"twenty":-7.228256,"median":-4.393309,"eighty":-3.543713,"marketCap":1003076183},{"date":"2025-06-13","current":-5.115786,"twenty":-7.156112,"median":-4.413455,"eighty":-3.545748,"marketCap":1068861565},{"date":"2025-06-20","current":-4.356073,"twenty":-7.062301,"median":-4.413455,"eighty":-3.549094,"marketCap":910131699},{"date":"2025-06-27","current":-4.627605,"twenty":-6.984824,"median":-4.413846,"eighty":-3.558149,"marketCap":966864047},{"date":"2025-07-03","current":-4.5525,"twenty":-6.978207,"median":-4.413846,"eighty":-3.566238,"marketCap":951172121},{"date":"2025-07-11","current":-4.610273,"twenty":-6.959266,"median":-4.434912,"eighty":-3.576816,"marketCap":963242833},{"date":"2025-07-18","current":-4.878917,"twenty":-6.905553,"median":-4.448509,"eighty":-3.590436,"marketCap":1019371645},{"date":"2025-07-25","current":-5.084011,"twenty":-6.899536,"median":-4.462257,"eighty":-3.592447,"marketCap":1062222673},{"date":"2025-08-01","current":-4.902026,"twenty":-6.889009,"median":-4.488402,"eighty":-3.59611,"marketCap":1024199930},{"date":"2025-08-08","current":-4.450911,"twenty":-6.843738,"median":-4.500505,"eighty":-3.597671,"marketCap":920510630},{"date":"2025-08-15","current":-4.924039,"twenty":-6.770823,"median":-4.509171,"eighty":-3.60188,"marketCap":1018360185},{"date":"2025-08-22","current":-4.900675,"twenty":-6.760445,"median":-4.52404,"eighty":-3.616232,"marketCap":1013528108},{"date":"2025-08-29","current":-4.883151,"twenty":-6.744059,"median":-4.5525,"eighty":-3.624946,"marketCap":1009904051},{"date":"2025-09-05","current":-4.962006,"twenty":-6.704732,"median":-4.610273,"eighty":-3.625072,"marketCap":1026212310},{"date":"2025-09-12","current":-4.731283,"twenty":-6.670975,"median":-4.650968,"eighty":-3.630649,"marketCap":978495552},{"date":"2025-09-19","current":-4.474275,"twenty":-6.670975,"median":-4.610273,"eighty":-3.651563,"marketCap":925342707},{"date":"2025-09-26","current":-4.558971,"twenty":-6.651853,"median":-4.590463,"eighty":-3.659766,"marketCap":942858985},{"date":"2025-10-03","current":-4.667031,"twenty":-6.651853,"median":-4.640746,"eighty":-3.671275,"marketCap":965207340},{"date":"2025-10-10","current":-6.182794,"twenty":-6.639187,"median":-4.66411,"eighty":-3.682866,"marketCap":1278688323},{"date":"2025-10-17","current":-6.495292,"twenty":-6.589022,"median":-4.675298,"eighty":-3.682866,"marketCap":1343317350},{"date":"2025-10-24","current":-8.382293,"twenty":-6.651853,"median":-4.679157,"eighty":-3.689208,"marketCap":1733575542},{"date":"2025-10-31","current":-9.090497,"twenty":-6.704732,"median":-4.696933,"eighty":-3.700564,"marketCap":1880042140},{"date":"2025-11-07","current":-11.662076,"twenty":-6.790267,"median":-4.714264,"eighty":-3.706047,"marketCap":1737287790},{"date":"2025-11-14","current":-11.787083,"twenty":-6.900444,"median":-4.731283,"eighty":-3.707046,"marketCap":1755909901},{"date":"2025-11-21","current":-12.224606,"twenty":-6.988263,"median":-4.745208,"eighty":-3.707046,"marketCap":1821087291},{"date":"2025-11-28","current":-15.625828,"twenty":-7.239349,"median":-4.751954,"eighty":-3.713244,"marketCap":2327763900},{"date":"2025-12-05","current":-17.454049,"twenty":-7.296115,"median":-4.772037,"eighty":-3.728167,"marketCap":2600112276},{"date":"2025-12-12","current":-17.896781,"twenty":-7.380142,"median":-4.779357,"eighty":-3.742192,"marketCap":2666065586},{"date":"2025-12-19","current":-17.433215,"twenty":-7.489402,"median":-4.800924,"eighty":-3.751648,"marketCap":2597008591},{"date":"2025-12-26","current":-17.214453,"twenty":-7.525937,"median":-4.815979,"eighty":-3.763383,"marketCap":2564419896},{"date":"2026-01-02","current":-17.063404,"twenty":-7.573901,"median":-4.841253,"eighty":-3.771122,"marketCap":2541918178},{"date":"2026-01-09","current":-15.698748,"twenty":-7.596248,"median":-4.85056,"eighty":-3.792677,"marketCap":2338626798},{"date":"2026-01-16","current":-17.235288,"twenty":-7.641035,"median":-4.868549,"eighty":-3.827277,"marketCap":2567523581},{"date":"2026-01-23","current":-17.756149,"twenty":-7.65516,"median":-4.878917,"eighty":-3.836222,"marketCap":2645115711},{"date":"2026-01-30","current":-17.49051,"twenty":-7.716495,"median":-4.891913,"eighty":-3.850233,"marketCap":2605543725},{"date":"2026-02-06","current":-17.157159,"twenty":-7.797537,"median":-4.900675,"eighty":-3.876725,"marketCap":2555884762},{"date":"2026-02-13","current":-18.146794,"twenty":-7.885881,"median":-4.903471,"eighty":-3.891573,"marketCap":2703309809},{"date":"2026-02-20","current":-23.527864,"twenty":-7.934432,"median":-4.916265,"eighty":-3.909092,"marketCap":3504922382},{"date":"2026-02-27","current":-21.83597,"twenty":-8.038472,"median":-4.931737,"eighty":-3.918816,"marketCap":3389008076},{"date":"2026-03-06","current":-20.540487,"twenty":-8.323214,"median":-4.953617,"eighty":-3.922049,"marketCap":3187945256},{"date":"2026-03-13","current":-20.449399,"twenty":-8.618907,"median":-4.962688,"eighty":-3.925813,"marketCap":3173808027},{"date":"2026-03-20","current":-21.41089,"twenty":-8.906386,"median":-4.973688,"eighty":-3.927002,"marketCap":3323034338},{"date":"2026-03-27","current":-24.0474,"twenty":-8.969358,"median":-4.994463,"eighty":-3.931452,"marketCap":3732228593},{"date":"2026-04-02","current":-24.745746,"twenty":-9.172768,"median":-5.075907,"eighty":-3.931939,"marketCap":3840614019},{"date":"2026-04-10","current":-26.198104,"twenty":-9.23713,"median":-5.085831,"eighty":-3.944911,"marketCap":4066024290},{"date":"2026-04-17","current":-38.738151,"twenty":-9.365612,"median":-5.125877,"eighty":-3.981637,"marketCap":6012277252},{"date":"2026-04-24","current":-38.48249,"twenty":-9.54815,"median":-5.141783,"eighty":-3.990939,"marketCap":5972597947},{"date":"2026-05-01","current":-41.378125,"twenty":-11.574571,"median":-5.163524,"eighty":-3.996385,"marketCap":6422009203},{"date":"2026-05-08","current":-35.378246,"twenty":-11.912235,"median":-5.194337,"eighty":-4.002987,"marketCap":6348095594},{"date":"2026-05-15","current":-36.612371,"twenty":-12.227731,"median":-5.199556,"eighty":-4.01025,"marketCap":6569540789},{"date":"2026-05-22","current":-35.96869,"twenty":-12.66317,"median":-5.24323,"eighty":-4.012918,"marketCap":6454041922},{"date":"2026-05-29","current":-34.899115,"twenty":-14.84662,"median":-5.263514,"eighty":-4.014565,"marketCap":6262122753},{"date":"2026-06-05","current":-37.982008,"twenty":-15.625828,"median":-5.295394,"eighty":-4.016676,"marketCap":6815301535},{"date":"2026-06-12","current":-39.0903,"twenty":-15.934177,"median":-5.346464,"eighty":-4.018572,"marketCap":7014168004},{"date":"2026-06-18","current":-42.342582,"twenty":-16.532126,"median":-5.375072,"eighty":-4.022327,"marketCap":7597741224},{"date":"2026-06-26","current":-42.913667,"twenty":-16.744637,"median":-5.470693,"eighty":-4.034149,"marketCap":7700213903},{"date":"2026-07-02","current":-43.020141,"twenty":-17.038402,"median":-5.524211,"eighty":-4.045526,"marketCap":7719318979},{"date":"2026-07-10","current":-47.79209,"twenty":-17.157159,"median":-5.623342,"eighty":-4.04736,"marketCap":8575573733},{"date":"2026-07-17","current":-46.12579,"twenty":-17.21862,"median":-5.641652,"eighty":-4.048014,"marketCap":8276581215},{"date":"2026-07-24","current":-49.002526,"twenty":-17.305083,"median":-5.684807,"eighty":-4.051257,"marketCap":8792768335},{"date":"2026-07-31","current":-49.742539,"twenty":-17.37592,"median":-5.758017,"eighty":-4.05376,"marketCap":8925552415},{"date":"2026-08-07","current":-50.967094,"twenty":-17.454049,"median":-5.886958,"eighty":-4.070861,"marketCap":9118930466},{"date":"2026-08-14","current":-50.193372,"twenty":-17.542596,"median":-5.928557,"eighty":-4.072986,"marketCap":8980497659},{"date":"2026-08-21","current":-53.120702,"twenty":-17.704063,"median":-5.957984,"eighty":-4.07743,"marketCap":9504249805},{"date":"2026-08-28","current":-46.135027,"twenty":-18.037414,"median":-6.00579,"eighty":-4.082736,"marketCap":8254386729}],"updateTime":1788216384834},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SYRE\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2643034592","title":"Spyre Therapeutics announces SKYLINE trial achieves primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2643034592","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643034592?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:18","pubTimestamp":1781525886,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) announced 12-week induction data from Part A of the Phase 2 SKYLINE trial of SPY002, an anti-TL1A being investigated for ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-announces-skyline-trial-achieves-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-announces-skyline-trial-achieves-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SYRE","BK4007","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643203841","title":"Spyre says SPY002 hits primary endpoint in Phase 2 SKYLINE ulcerative colitis trial Part A induction data","url":"https://stock-news.laohu8.com/highlight/detail?id=2643203841","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643203841?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:03","pubTimestamp":1781525029,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics reported positive 12-week Part A induction results from the Phase 2 SKYLINE trial of SPY002 in moderate-to-severe ulcerative colitis.The study met its primary goal, showing meaningful improvements in tissue-level disease activity, symptoms, and endoscopic findings.SPY002 was well tolerated, with serious adverse events reported as not drug-related and no drug-related serious safety signals highlighted.The program moved into enrollment for Part B, a randomized, placebo-controlled stage testing SPY002 doses and combination regimens within the SKYLINE platform.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL7Flksl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014005.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","IE00BKPKM429.USD","LU2210149790.SGD","LU2210150020.SGD","SG9999014013.SGD","BK4588","SG9999014021.USD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","SG9999014039.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK4112","IE00B3QW5Z07.USD","NDAQ","SYRE","IE00BN0W2V16.EUR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643720801","title":"Spyre Therapeutics - Spy002 Meets Primary Endpoint With 10.7-Point Rhi Reduction at Week 12","url":"https://stock-news.laohu8.com/highlight/detail?id=2643720801","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643720801?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:00","pubTimestamp":1781524803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA3TZVV7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643208067","title":"Spyre Announces Potential Best-in-Class Spy002 (Anti-Tl1a) Part a Induction Results From Skyline Trial in Moderate-to-Severe Ulcerative Colitis Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2643208067","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643208067?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:00","pubTimestamp":1781524803,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA3TZVV7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643080622","title":"Spyre Therapeutics - Spy002 Well Tolerated With Safety Profile Consistent With Tl1a Class","url":"https://stock-news.laohu8.com/highlight/detail?id=2643080622","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643080622?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:00","pubTimestamp":1781524803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA3TZVV7:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643021208","title":"Spyre Therapeutics - Spy002 Achieves 33% Clinical Remission and 42% Endoscopic Improvement at Week 12","url":"https://stock-news.laohu8.com/highlight/detail?id=2643021208","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643021208?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:00","pubTimestamp":1781524803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA3TZVV7:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643000208","title":"Spyre Therapeutics - Twenty Subjects Had Treatment-Emergent Adverse Events; Two Serious, None Drug-Related","url":"https://stock-news.laohu8.com/highlight/detail?id=2643000208","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643000208?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:00","pubTimestamp":1781524803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA3TZVV7:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643369203","title":"Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2643369203","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643369203?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:00","pubTimestamp":1781524800,"startTime":"0","endTime":"0","summary":"SPY002 met its primary endpoint with a statistically significant reduction of 10.7 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score Secondary endpoints included ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/15/3311741/0/en/Spyre-Announces-Potential-Best-in-Class-SPY002-anti-TL1A-Part-A-Induction-Results-from-SKYLINE-Trial-in-Moderate-to-Severe-Ulcerative-Colitis-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHI","BK4213","BK4588","BK4130","BK4139","LU0054578231.USD","BK4585","SD","BK4533","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643722803","title":"Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Cogstate Ltd (COGZF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643722803","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643722803?lang=en_us&edition=fundamental","pubTime":"2026-06-15 07:40","pubTimestamp":1781480431,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spyre Therapeutics (SYRE) and Cogstate Ltd (COGZF) w...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-spyre-therapeutics-syre-cogstate-ltd-cogzf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-spyre-therapeutics-syre-cogstate-ltd-cogzf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SYRE","COGZF","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642487289","title":"S&P 500 Futures Climb In Premarket Trading; Navan, AXT Lead","url":"https://stock-news.laohu8.com/highlight/detail?id=2642487289","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642487289?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:31","pubTimestamp":1781177460,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Barrons.com using technology from Automated Insights.With U.S. stock markets set to open in two hours, Navan Inc. Cl A  was up 19.0% in pre-market trading, and AXT Inc.  was up 7.3%.Spyre Therapeutics Inc. , Coupang Inc. , and Tower Semiconductor Ltd.  were all posting gains of at least 6%. In early trading, Oracle Corp.  and Illinois Tool Works Inc.  had posted declines, falling 8.1% and 4.5%, respectively.Meanwhile S&P 500 futures were up 0.60%, with futures for the Dow Jones Industrial Average rising 0.69%. The Cboe Volatility Index futures were up 10.03%.In commodities news, Brent crude oil futures were down 1.17%, while gold futures were down 0.64%. Bitcoin climbed 1.93% to $63,095.In the previous regular trading session, the S&P 500 and the Dow were down 1.62% and 1.87%, respectively. Stocks in Asia were mixed overnight, with Japan's NIKKEI 225 Index up 0.06% and China's Shanghai Composite Index down 0.16%.In afternoon trading, stocks i","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4543","SPHQ","LU0082616367.USD","SMAX","LU2357305700.SGD","BK4533","LU1861220033.SGD","LU1046421795.USD","VTV","LU2746668974.SGD","IE0009356076.USD","ORCL","SPYH","LU1803068979.SGD","BK4548","LU0957808578.USD","LU1720051108.HKD","SPYU","LU1035773651.USD","SPUU","LU0175139822.USD","LU0353189763.USD","ORCS","IJR","LU1934455194.USD","JEPI","DBSC","LU0157215616.USD","LU1037948541.HKD","RSPN","SSO","ITW","SG9999001424.SGD","LU2087625088.SGD","GPIX","IE00B7SZLL34.SGD","LU1691799644.USD","LU0256863811.USD","ORCX","LU0965508806.USD","VTI","IE00B42XCP33.USD","NOBL","SPLV","LU2237957902.USD","XDTE","LU1642822529.SGD","LU2237957811.SGD","LU2860962120.EUR","LU1003077747.HKD","LU0738911758.USD","LU1435385759.SGD","LU1548497426.USD","LU0289960550.SGD","SPYQ","VEU","LU2896262040.SGD","RSP","LU1366333091.USD","DMAX","IE00BDGV0183.EUR","LU0353189680.USD","LU1935043023.USD","VV","UPRO","SPXU","BK4585","LU0081259029.USD","LU1242518857.USD","LU0980610538.SGD","ACWI","BK4139","ORCU","LU0985489474.SGD","LU0661504455.SGD",".SPX","LU1235294995.USD","YSPY","IE00B3PB1722.GBP","CPNG","LU1934455863.HKD","HIBL","LU1934455277.USD","LU0070302665.USD","NAVN","BMAY","SDS","LU2458330169.SGD","LU0553294199.USD","SPDN","LU1201861249.SGD","IE0002270589.USD","LU2290526834.HKD","LU0198837287.USD","LU2458330243.SGD","BK4528","BK4581","LU0648001328.SGD","LU1506573853.SGD","IE00BGHQF631.EUR","LU0208291251.USD","LU2746668461.USD","RSPU","ALLW","IJH","IE00B19Z3B42.SGD","SPMO","LU0210536198.USD","LU1242518931.SGD","LU1852331112.SGD","LU0320765489.SGD","SG9999003800.SGD","BK4161","LU1720051017.SGD","LU0068578508.USD","LU0965509101.SGD","LU0348723411.USD","BK4220","LU2250418816.HKD","LU0444973449.USD","BK4141","LU1429558221.USD","IE00BMPRXR70.SGD","LU2054465674.USD","BK4142","LU2360107168.USD","IE00BVYPNV92.GBP","IE00BMPRXQ63.HKD","LU0109392836.USD","LU0949170772.SGD","MMAX","SH","LU2543165471.USD","XYLD","LU1069347547.HKD","LU2236285917.USD","IE00BBT3K403.USD","LU1989772923.USD","MOAT","TSPY","IE00B5949003.HKD","LU0444971666.USD","LU2108987350.USD","BK4147","LU1823568750.SGD","SYRE","BK4122","LU0889565833.HKD","BK4534","IE00BN8TJ469.HKD","SPYG","HIBS","LU1935042215.USD","SPUS","IE0004445239.USD","SPYM","SFY","IE00B775SV38.USD","SPHD","LU1935042991.SGD","BK4566","IE00B19Z3581.USD","LU1989764748.USD","LU0476273544.USD","IVE","LU0965509283.SGD","LU1989764664.SGD","SG9999011175.SGD","LU1935042488.USD","AXTI","LU1989772840.SGD","LU0878866978.SGD","LU0433182093.SGD","LU0234570918.USD","IVV","LU0545039389.USD","LU2326559502.SGD","SPYD","IE00BMPRXN33.USD","IE00BLSP4452.SGD","SCHB","SPXS","IE00B3S45H60.SGD","LU0719512351.SGD","IE00BVYPNW00.USD","LU1366192091.USD","LU0323591593.USD","LU1861215975.USD","LU1489326972.SGD","SPYV","SCHX","TSEM","LU0979878070.USD","LU0234572021.USD","LU0417517546.SGD","LU0130102774.USD","ETFT","BK4516","VBK","BK4588","BK4097","BK4538","ITOT","LU1815336760.USD","IVW","LU0056508442.USD","IE00BLSP4239.USD","LU0314106906.USD","LU2360106780.USD","LU1037948897.HKD","RSPA","SPXL","SPGP","XLG","LU0965509010.AUD","GSLC","LU1935043536.SGD","LU0861579265.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641147289","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2641147289","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641147289?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:01","pubTimestamp":1780689660,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., June  05, 2026  (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/05/3307598/0/en/Spyre-Therapeutics-Announces-Grants-of-Inducement-Awards.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","LENZ","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640154829","title":"Spyre Therapeutics  : Deutsche Bank Raises Target Price to $115 From $102","url":"https://stock-news.laohu8.com/highlight/detail?id=2640154829","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640154829?lang=en_us&edition=fundamental","pubTime":"2026-06-04 19:05","pubTimestamp":1780571110,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nAQN2M22WT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640713305","title":"Spyre Therapeutics CMO Sheldon Sloan disposes of USD 624,975 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2640713305","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640713305?lang=en_us&edition=fundamental","pubTime":"2026-06-04 09:32","pubTimestamp":1780536766,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Chief Medical Officer Sheldon Sloan exercised stock options for 8,333 shares at USD 27.46 on June 3.Sloan sold 8,333 shares the same day at USD 75, ending with 0 shares owned directly.Sloan reported 313,334 stock options beneficially owned following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL2qGS39:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640080133","title":"Spyre Therapeutics CEO Cameron Turtle disposes of USD 1.04 million in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2640080133","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640080133?lang=en_us&edition=fundamental","pubTime":"2026-06-04 09:31","pubTimestamp":1780536709,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics CEO and director Cameron Turtle sold 14,000 common shares on June 1, 2026.Sales were priced at $69.4 to $71.38 per share.Post-transaction beneficial ownership stood at 597,540 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL4hKsHC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Spyre Therapeutics CEO Cameron Turtle disposes of USD 1.04 million in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640330511","title":"Spyre Therapeutics CFO Scott L Burrows disposes of common shares worth $534,123.87","url":"https://stock-news.laohu8.com/highlight/detail?id=2640330511","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640330511?lang=en_us&edition=fundamental","pubTime":"2026-06-04 09:31","pubTimestamp":1780536676,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics CFO Scott L. Burrows cut his stake to 97,994 shares in transactions dated June 1.Disposed of 7,500 shares via option exercise at USD 14.5, then sold 7,500 shares at weighted-average prices of USD 69.75 to USD 72.06.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL9vFR2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640418210","title":"Assessing Spyre Therapeutics (SYRE) Valuation After Expanded SPY003 License With Paragon","url":"https://stock-news.laohu8.com/highlight/detail?id=2640418210","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640418210?lang=en_us&edition=fundamental","pubTime":"2026-06-04 04:18","pubTimestamp":1780517919,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) stock is back in focus after the company amended its SPY003 license with Paragon Therapeutics, expanding rights beyond inflammatory bowel disease to broader uses while keeping clear dosing limits for non IBD indications.\nSee our latest analysis for Spyre Therapeutics.\nThe expanded SPY003 license and recent conference appearance come after a sharp run, with the stock’s 90 day share price return of 68.68% and a very large 1 year total shareholder return. However, the 7...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/assessing-spyre-therapeutics-syre-valuation-after-expanded-s","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/assessing-spyre-therapeutics-syre-valuation-after-expanded-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640042359","title":"Spyre Therapeutics Completes Enrollment in Phase 2 SKYWAY Trial of SPY072 in Rheumatic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2640042359","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640042359?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:45","pubTimestamp":1780490747,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics  has completed enrollment in all sub-studies of its phase 2 SKYWAY basket trial of SPY072 in rheumatic diseases, the company said Wednesday.The completed enrollment across the sub-studies keeps the company's planned slate of six phase 2 data readouts in 2026 on track, Spyre Therapeutics said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4539","SYRE","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640901929","title":"Spyre Therapeutics - Across Skyway and Skyline Trials, Planned ‘6 in ’26’ Phase 2 Readouts Enabled and on Track","url":"https://stock-news.laohu8.com/highlight/detail?id=2640901929","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640901929?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:00","pubTimestamp":1780488000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nTUA8HWG8M:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640019429","title":"Spyre Therapeutics - Reiterates Expected Q3 2026 Readout for Rheumatoid Arthritis (Ra) and Q4 2026 Readouts for Psa and Axspa","url":"https://stock-news.laohu8.com/highlight/detail?id=2640019429","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640019429?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:00","pubTimestamp":1780488000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nTUA8HWG8M:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640015379","title":"Spyre Therapeutics Announces Completion of Enrollment in Skyway Basket Trial Evaluating Spy072 (Anti-Tl1a) in Ra, Psa, and Axspa","url":"https://stock-news.laohu8.com/highlight/detail?id=2640015379","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640015379?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:00","pubTimestamp":1780488000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nTUA8HWG8M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":4,"totalSize":175,"code":"91000000","status":"200"}]}}